Form 4: DaVita Inc. COO David Maughan Reports Stock Transactions
SEC Form 4 Filing
DaVita Inc.'s Chief Operating Officer, David Paul Maughan, reports acquisition and disposal of company stock and stock appreciation rights on March 15, 2025.
Summary
- David Paul Maughan, Chief Operating Officer of DaVita Inc., filed a Form 4 detailing changes in beneficial ownership of the company's securities.
- On March 15, 2025, Maughan acquired 5,228 shares of common stock at $0 and disposed of 5,021 shares at $143.45 to cover tax obligations related to vesting restricted stock units granted on March 15, 2021.
- An additional 4,312 shares were disposed of at $143.45 to cover tax obligations related to vesting restricted stock units granted on March 15, 2022.
- Maughan also acquired 14,474 stock appreciation rights (SARs) with an exercise price of $143.45, vesting in two tranches on March 15, 2028, and March 15, 2029, expiring on March 15, 2030.
- Following these transactions, Maughan directly owns 129,767 shares of DaVita Inc. common stock and 14,474 stock appreciation rights.
Sentiment
Score: 6
Explanation: Neutral sentiment. The transactions are routine and related to compensation. There's no indication of significant concern or excitement.
Positives
- Maughan's acquisition of 5,228 shares, even if related to compensation, could be seen as a positive signal.
Negatives
- The disposal of 5,021 and 4,312 shares to cover tax obligations could be perceived as a slight negative, although it's a common practice.
Risks
- Significant stock sales by insiders could potentially negatively impact investor sentiment.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules of the restricted stock units and stock appreciation rights indicate future compensation plans.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Monitoring these filings can offer insights into management's perspective on the company's valuation and future prospects.
Comparison to Industry Standards
- Stock-based compensation is a common practice in the healthcare industry, including companies like UnitedHealth Group (UNH) and CVS Health (CVS).
- The vesting schedules and terms of the restricted stock units and stock appreciation rights are generally consistent with industry norms for executive compensation packages.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments.
Key Dates
| Date | Description |
|---|---|
| 03/15/2021 | Date of grant for restricted stock units related to tax obligation. |
| 03/15/2022 | Date of grant for restricted stock units related to tax obligation. |
| 03/15/2025 | Date of transactions: stock acquisition, disposals, and SARs acquisition. |
| 03/15/2028 | First vesting date (50%) for restricted stock units and stock appreciation rights. |
| 03/15/2029 | Second vesting date (50%) for restricted stock units and stock appreciation rights. |
| 03/15/2030 | Expiration date for stock appreciation rights. |
| 03/18/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.